Alpha Crest Capital Management LLC Atara Biotherapeutics, Inc. Transaction History

Alpha Crest Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$4.69 - $9.84 $99,897 - $209,592	-21,300 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$8.44 - $16.89 $78,610 - $157,313	9,314 Added 77.71%	21,300 $198,000
Q4 2021 Feb 09, 2022	BUY	$14.7 - $19.89 $176,194 - $238,401	11,986 New	11,986 $189,000
Q2 2021 Aug 12, 2021	SELL	$12.89 - $16.58 $394,434 - $507,347	-30,600 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$14.0 - $20.72 $428,400 - $634,032	30,600 New	30,600 $439,000

Q3 2020 Nov 12, 2020	SELL	$11.92 - $15.87 $154,960 - $206,310	-13,000 Closed	0 $0
Q2 2020 Aug 12, 2020	BUY	$7.53 - $14.93 $97,890 - $194,090	13,000 New	13,000 $189,000

85M

18.4K

51.3K

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $728M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Alpha Crest Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Crest Capital Management LLC with notifications on news.